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Abstract
On the basis of the Survey of Health, Ageing, and Retirement (SHARE), we analyse the determinants of who
engages in mammography screening focusing on European women aged 50-69 years. A special emphasis is put
on the measurement error of subjective life expectancy and on the measurement and impact of physician quality.
Our main findings are that physician quality, better education, having a partner, younger age and better health are
associated with higher rates of receipt. The impact of subjective life expectancy on screening decision substantially
increases after taking measurement error into account.
JEL Classification: C 36, I 11, I 18
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Introduction
Breast cancer is the most common cause of cancer
deaths among women in the member states of the
European Union [1]. According to estimates of inci-
dence and mortality by the International Agency for
Research on Cancer (IARC), there were 331,000 new
cases and 90,000 deaths due to breast cancer in the EU
in 2006 [1]. Breast cancer accounts for almost one out
of three new cancer cases and one out of six (17%) can-
cer deaths. One in nine women gets breast cancer at
some point in her life and one in thirty perishes as a
consequence of the disease [2]. Due to demographic
trends, significantly more women per capita will be con-
fronted with this disease in the future [3].A Moreover
breast cancer is associated with high costs for national
health care accounting to about 0.5-0.6% of the total
health care expenditure of developed countries [2].
Breast cancer takes years to develop. At the onset of
the disease, most breast cancers cause no symptoms. As
long as cancer has not metastasized, i.e. that has not
moved to the lymph system or to other organs of the
body, patients have a five-year survival rate of 96%. If
the cancer has spread to the nearby lymph nodes, the
rate drops down to 81%. Women whose breast cancer
has metastasized to other organs of the body have a
five-year survival rate of 26% [4].
A mammogram screening is the best tool available for
detecting breast cancer in the early stage, i.e. before
symptoms appear. Mammography can detect a breast
lump before it can be palpated; it can save live by detect-
ing breast cancer in the earliest stage. For women aged
50- 69 years, mammography has been shown to lower
the risk of dying from breast cancer by 35% [4]. In addi-
tion it has shown to be highly cost-effective for women
in this age group [5]. In light of the evidence available,
the International Agency for Research on Cancer expert
working group (IARC Working Group, [6]) advises that
mammography screening should be offered as a public
health policy directed to women aged 50-69 every two
years in order to reduce the risk of death from breast
cancer. EU guidelines [7] promote a target screening rate
of at least 75% of eligible women in European countries.
Even though mammography is officially recommended
both on the national and European level, screening rates
in most European countries remain far from 100%. B For
example, in the Slovak Republic only around 20% of
women aged 50-69 years are screened annually [2].
Correspondingly, increasing mammography for women
aged 50-69 years is an important public health goal in
Europe [1].
There exists a considerable amount of empirical and
theoretical research in health economics on the predictors
of screening and preventive behaviour. Theoretical eco-
nomic models include those of Grossman [8], Cropper [9],
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Giuffrida and Gravelle [10], Byrne and Thompson [11],
Howard [12] or Fang and Wang [4]. Jepson et al. [13] and
Schueler et al. [14] provide good reviews of the empirical
literature on determinants of mammography screening
uptake and recommendations for increasing uptake.
Although the literature on factors associated with mam-
mography screening is abundant, the reasons for under-
participation remain unclear, because empirical results are
inconclusive and still incomplete. Identifying the reasons
behind lower screening rates is of high importance, since
screening is a crucial first step in the process of early
detection and treatment. Once the disease is detected,
medical providers and the health care system have a major
influence in what is done [15].
The purpose of this paper is to conduct an empirical
analysis of the determinants of participation in mammo-
graphy screening. The analysis focuses on European
women aged 50-69 years. The data base used is the first
and second wave of the Survey of Health Aging and
Retirement in Europe (SHARE). The impact of physician
quality on screening decisions will be of special interest.
No empirical study so far includes physician quality as a
potential factor for the decision for screening. The rea-
son is that survey data including this information are
scarce. C Physician quality can be expected to influence
the decision for screening, since asymmetric information
is particularly widespread in health care markets often
forcing expert physicians to act on behalf of their less
informed patients [16]. Furthermore, individual percep-
tion of risks is often biased (e.g. [17]). Breast cancer is
no exception in this regard and even women with a
high risk of getting breast cancer tend to have false
perceptions of the risks and the seriousness of breast
cancer [18]. For this reason, physicians often need to act
as agents for their less-informed patients, and they play
an important role in determining mammography screen-
ing take-up. Empirical evidence clearly indicates that
women follow physician advice for mammography
screening (e.g. [19,20]). Thus, we hypothesize that a bet-
ter physician - as measured by an index defined in the
next section - will more often suggest mammography
screening in line with the official national and EU
screening guidelines, thus inducing higher screening
rates.
A second focus lies on the impact of subjective live
expectancy on mammography screening. Economic the-
ory suggests [21,22] that the motivation to invest in one’s
own health should depend on the subjective life expec-
tancy. Women who expect a longer life should be more
inclined to invest in health in order to spend more years
in good health than women expecting to live only for
another few years. A corresponding phenomenon has
been empirically detected for smoking behaviour in the
US-context by Fang et al. [23] who call it the “Mickey
Mantle Effect”.D However, empirical analysis has to
consider that stated life expectancy suffers from measure-
ment error, leading to attenuation bias. Moreover life
expectancy may be endogenous mainly due to reverse
causality: investment in health increases life expectancy.
We follow Fang et al. [23] and apply their empirical
approach to mammography take-up and control for mea-
surement error and endogeneity of the subjective life
expectancy through an IV-approach.
The results show that better physician quality, better
education, being married, being a “high user” of health
care, younger age and better health are associated with
higher rates of screening take-up. Moreover subjective
life expectancy strongly influences screening probability
once the measurement error is controlled for.
The remainder of the paper is organized as follows:
The next section provides some information on the data
set and the theoretical and empirical screening determi-
nants. Then the empirical strategy is described, followed
by the results. The final section discusses the results
and adds some concluding remarks.
Data, determinants of mammography screening
and variables
Data
We use data from the first (2004) and second (2006)
wave of the Survey of Health, Ageing and Retirement in
Europe (SHARE) to analyze the determinants of mam-
mography screening. SHARE is a large representative
micro data set of more than 30,000 individuals above
the age of 50 years from 14 European countries and
Israel starting in 2004. It provides detailed information
on health status and on a variety of other socioeconomic
characteristics. The data was collected using a computer
assisted personal interviewing (CAPI) program, supple-
mented by a self-completion paper and pencil question-
naire.E This “drop-off questionnaire” includes additional
questions which address issues like physician behaviour
or utilization of preventive health care. Furthermore it
includes a question about mammography take-up in the
last two years. This questionnaire was only sent to a
subgroup of the sample and no respondent received it
in both waves.
We restrict our sample to women aged 50-69 years,
since for this group mammography screening is officially
recommended at both European level and the national
level of the countries included. In addition, we exclude
women if they reported a history of cancer as they are
not representative and we discard observations with
missing or unreliable values for the variables of interest
and the other explanatory variables. Therefore, our esti-
mation sample consists of two cross-sections with 6,893
women in total (4,412 from the first wave surveyed in
2004 and 2,481 from the second wave surveyed in 2006).
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Table 1 provides descriptive statistics of the variables
included in the empirical analysis.
Determinants of mammography screening and variables
Economic theory suggests all variables mentioned in
Table 1 could be important determinants of individual
screening decision. From an economic perspective the
decision to undergo mammography screening is an
investment decision. Such an investment is worthwhile
if the expected present value of the reduction in disease
and in the probability of death is larger than the oppor-
tunity costs of the intervention (comp. [8,9,24,25] for a
formalization of these notions). However, the question
whether people actually decide to invest in mammogra-
phy screening is largely an empirical one as we will
argue in the following paragraphs. The paragraphs dis-
cuss certain hypotheses that would seem to be implied
by economic theory and relate them to existing empiri-
cal results. Moreover the paragraphs describe the vari-
ables that we use in the empirical analysis in order to
test the hypotheses.
Age
First of all, according to economic theory, age should
influence mammography screening decision but the the-
oretical impact is offsetting. According to health human
Table 1 Sample Means and Description Variable Definition
Variable Definition Mean (N = 6,893)
Variables from Wave 1 and 2 of the SHARE Dependent Variable
Mammogram Mammogram screening in the last two years (Yes = 1, No = 0) 0.647
Explanatory Variables
Physician Quality Index GP quality between 0 and 1 as explained in the text 0.301
Life Expectancy Self-stated probability of being alive in about 10 years 0.670
50 ≤ Age < 55 0.288
55 ≤ Age < 60 0.273
60 ≤ Age < 65 0.243
65 ≤ Age < 70 0.195
Self Assessed Health Excellent = 1 to poor = 5 2.907
Limitations in ADL Number of limitations in Activities of Daily Living 0.113
Heart Attack Chronic Conditions: Heart attack 0.067
Stroke Chronic Conditions: Stroke 0.019
Diabetes Chronic Conditions: Diabetes 0.074
Lung disease Chronic Conditions: Lung Disease 0.041
Has Partner Binary Variable for whether to women has a partner 0.744
Children in HH Number of children living in household 0.462
ISCED Low Education ISCED1 level between 0 and 2 0.444
Doctor visits ≥ 10 Number of doctor visits ≥ 10 within the previous 12 month 0.221
No drugs Binary Variable for whether the woman regularly takes prescription drugs 0.314
Hospital Stays ≥ 2 Number of hospital stays ≥ 2 within the previous 12 month
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capital models (based on [8]) health depreciates at an
increasing rate as one gets older, reducing the returns
on investment. Moreover, the potential years of life
saved due to mammography screening decline with age
[9]. Alternatively, older women should be more likely to
take-up mammography screening, because they have a
greater risk for breast cancer than younger women (e.g.
[26,27]) and thus expected benefits to mammography
screening should be higher for those at higher risk for
breast cancer. The great majority of empirical studies
however indicate that older women are less likely to
engage in mammography screening (e.g. [28,29]). To
account for age we include dummy variables of different
age groups. The reference age group that is not included
in the regression is the group of women aged 50-54
years.
Health status
Health Status should also be associated with the decision
for screening. Those in poorer health should be more
likely to undergo mammography screening, since they
potentially have higher cost to getting other diseases. For
example rehabilitation and treatment may be more diffi-
cult for people in poor health than for those who are
otherwise in good health [30]. Alternatively, it may be the
case that people in poor health have less time to receive
treatment or screens given their physical limitations.
Furthermore women - as well as the physician acting as
their agent [16]F - could set priority on other medical
measures when sick, since mammography is associated
with a future related and uncertain benefit [31]. Overall, it
remains largely an empirical question whether poor health
is associated with more or less mammography screening.
The empirical literature is inconclusive whether poor
health is a barrier to screening. To address this question,
we control for health using a detailed set of health indica-
tors. These include self-assessed health (i.e. excellent, very
good, good, fair, or poor), as well as a number of objective
measures such as binary indicators for whether the
respondent was ever diagnosed with stroke, heart disease,
lung disease and diabetes as well as an index of limitations
in activities of daily living (ADLs).G ADLs refer to daily
self-care activities within an individual’s place of residence,
in outdoor environments, or both.
Table 1 Sample Means and Description Variable Definition (Continued)
Instruments
Father Age at 0.262
Death ≤ 65
Father Age at Death 0.111
65 to 69
Father Age at Death 0.111
70 to 74
Father Age at Death 0.126
75 to 79
Father Age at Death 0.139
80 to 84
Father Age at 0.093
Death ≥ 85
Age Father_IV Age at death or current age of father if still alive 72.02
Mother Age at 0.144
Death ≤ 65
Mother Age at Death 0.070
65 to 69
Mother Age at Death 0.092
70 to 74
Mother Age at Death 0.116
75 to 79
Mother Age at Death 0.125
80 to 84
Mother Age at 0.118
Death ≥ 85
Age Mother_IV Age at death or current age of mother if still alive 76.64
1International Standard Classification of Education
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Education and cognitive abilities
Better education may increase the use of screening ser-
vices, implying more efficiency in producing health (e.g.
[8]). For example, a better educated woman may be more
likely to understand the benefits of mammography screen-
ing. In addition, these women may be more prone to
recognize the early warning signs of breast cancer and be
more apt to visit a physician when symptoms first occur.
Education is captured by a dummy variable for low educa-
tion as defined by ISCED equivalents.H Since educational
attainment in the past might not fully mirror the current
skills to process information [32], we also analyse the role
of current cognitive abilities. An increasing body of
research suggests that differences in cognition partly
explain variations in health behaviours (compare [33]).
Cutler and Lleras-Muney [34] show that disparities in cog-
nitive ability can account for about 30% of the average
education gradient in a wide variety of health behaviors in
Great Britain and the United States. In addition, cognitive
ability at later ages seems to be more important than that
measured earlier in life [33]. In this paper cognitive abil-
ities are captured by the variables “recall” and “verbal flu-
ency”. Both are often used as proxies for cognitive abilities
in empirical work (e.g. [35]). Verbal fluency is measured
by the number of different animals the respondent is able
to state within one minute. Recall is measured by the
number of words the respondent can recall from a list of
ten words that has been shown her some minutes before.
Both measures reflect cognitive functions as identified by
the cognitive psychology literature [27]. Empirical studies
(e.g. [36]) find that cognitive impairment is associated with
lower screening mammography rates. We hypothesize that
the worse the cognitive skills the lower the probability to
screen, since cognitive impairments limit the patients’ abil-
ity to gather and process information.
By increasing the actual or perceived costs of proces-
sing information, they can act as a barrier for mammo-
graphy screening. The positive influence of information
on the demand of prevention is shown by Parente et al.
[37], who find that consumer knowledge has a substan-
tial positive effect on the use of preventive services.
Family structure
Having a partner should be associated with higher
screening rates as empirical studies reveal [34,38].
Responsibility for the partner might be important, since
spouses seem to encourage each other to a health-pro-
moting behaviour [39]. Those who have a partner and/
or have children are probably reminded more often of
the importance of mammography by their loved ones.
Thus living not alone should lower information costs.
We include controls for the number of children living
in the household and a dichotomous variable for
whether a woman has partner.
High users
Another factor for the screening decision should be how
much prior health care one has used. Some individuals
are simply “high users” of medical care, while others
may choose not to utilize health care, even when it is
readily available and affordable. Wu [28] finds empirical
evidence for this regarding mammography screening in
the US-context. To address “using behaviour” in the
European context, we follow the empirical strategy of
Wu [28] and include three dichotomous variables for
whether a women i) had at least ten doctor’s office visits
in the last year, ii) more than two hospital stays in the
last year and iii) regularly takes prescription drugs.
Life expectancy
The motivation to invest in one’s own health should
depend on the subjective life expectancy of the respon-
dent as well. Individuals who expect a longer life should
be more inclined to invest in health, since the potential
payoff of health investments is greater for people in good
health than for people who believe to live for a few more
years only [21]. Fang et al. [23] find that individuals who
expect a longer life are significantly less likely to be cur-
rently smoking. They find no effect, however, for other
health behaviours like heavy drinking or obesity. We cal-
culate a variable indicating subjective life expectancy
from following question of the SHARE: What are the
chances that you will live to be age 75/80/85/90/95/100/
105/110/120 or more?” (either 75 or current age plus
about 10 years). Based on panel data from the Health and
Retirement Study, Hurd and McGarry [40] analyzed the
ability of subjective survival probabilities to predict actual
mortality. Using panel data they found that subjective
survival probabilities are an adequate measure to predict
actual survival: those who survived in the panel reported
survival probabilities approximately 50% higher at base-
line compared to those who died.
Physician quality
Finally, we want to analyse the impact of physician qual-
ity on the decision to undergo mammography screening.
As argued by Maurer [41], health literacy of the typical
patient is limited, and patients rely heavily on their phy-
sician’s advice. Usually, they follow their doctor’s recom-
mendation, which also applies to mammography
screening. May et al. [19] find in an US-study that 66%
of women who received a recommendation adhered and
of women receiving a documented recommendation,
75% adhered. Alternatively Meissner et al. [20] found
for the US that 80% of non-screeners who reported hav-
ing access to health care did not receive a recommenda-
tion for a mammogram.
Unfortunately, we cannot test directly for the impact
of physician’s advice on the probability of screening
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decision. Therefore we follow Maurer [41] as well as
Schmitz and Wübker [42] and compute a physician
quality score and assume that better physicians are
more likely to recommend mammography screening.I
The idea behind this assumption is that better physi-
cians are more prone to follow national guidelines
regarding mammography screening and thus are more
likely recommend screening for women if it is indicated
(i.e. women aged 50 to 69 years). The quality score is
computed in the following way. We use the answers of
individuals to five questions in the drop-off question-
naire concerning specific geriatric assessments, which
any general practitioner should routinely perform. These
are how frequently a doctor i) asks about physical exer-
cise, ii) suggests regular physical exercise, iii) asks about
falls, iv) checks balance, and v) asks about drugs used.
We sum up all the answers where we assign the cate-
gory “at every visit” a 2, “at some visits” a 1 and “never”
a 0. Like Maurer [41] and Schmitz and Wübker [42] we
acknowledge that some questions are the more impor-
tant the older the women are and the less important the
younger the women are. Therefore, we do not consider
balance checks and queries about falls if the respondent
is aged 50-59. For women aged 60-69 we weight the
answers to these two questions with 0.5. To get a qual-
ity indicator that falls into the range of 0 and 1 we
divide the sum by the age-adjusted maximum possible
number of points. Clearly not performing these geriatric
assessments at every visit does not automatically reveal
a bad physician quality. The lack of time in the daily
routine might cause that a doctor does not perform
these aspects regularly and this may not automatically
reflect that the doctor does not assign women to mam-
mography if it is indicated. However, we think it is rea-
sonable to assume that physicians who perform these
assessments regularly are on average more prone to
recommend a mammography screening if it is indicated
compared to those who do not perform these aspects
regularly. This is supported by a strong positive correla-
tion between the quality-score and the recommendation
of a colonoscopy by a physician if it is indicated which
is also investigated in the SHARE.J
Empirical strategy and estimation results
Basic analysis
We apply two basic regression models: First the linear
probability model, that is, an OLS-regression of the vari-
able indicating a mammography screening on the
above-mentioned exogenous variables.K Second the pro-
bit regression model, which in contrast to the OLS-
regression imposes the restriction that a predicted value
lies inside the range of 0 and 1. To control for institu-
tional and cultural differences in screening behaviour we
include a full set of country dummies. Table 2 reports
the results of the linear probability model in the first
column.
The results indicate that physician quality has a posi-
tive and significant impact on the decision to undergo
mammography screening. L Specifically, our estimates
show on average 10.4%age points higher screening rates
among women whose family physician performs all ger-
iatric assessments relative to those whose doctor does
not undertake any evaluation. M
Given that the average screening rate in this age-
group is 64 percent, this is a considerable amount.
Besides physician quality, the main variable explaining
the demand for mammography screening is age. Older
women are less likely to get mammograms. In example,
being in the 65-69 age group decreases the probability of
getting a mammography screening by 9.5 percentages
points compared with the 50-54 age group (i.e. the refer-
ence group that is not included in the regression model).
Generally, sicker women as measured by objective and
subjective measures of health status are less likely to get
mammograms. More precisely, lower ability to perform
activities of daily living and suffering from chronic condi-
tions like a stroke and diabetes are similarly associated
with lower screening rates. Moreover, even after control-
ling for those objective measures of health status, worse
self assessed health is associated with lower mammogra-
phy screening rates. Education and the capability of pro-
cessing information affect the mammography screening
decision. Both having a higher than low education and
yielding more points in the verbal fluency test are asso-
ciated with higher screening rates. The number of chil-
dren in the household does not seem to play an
important role, whereas whether a woman has a partner
significantly increases the screening probability.
Being “high-users” of medical care is significantly posi-
tive associated with mammography screening. Specifi-
cally, our estimates show on average 5.5 percentage
points higher screening rates among women who regu-
larly take drugs compared to women who do not take
drugs regularly. Moreover, women who had at least ten
doctor visits in the last year have on average 4 percentage
points higher screening rates than those with less than
ten doctor visits.
Finally, higher subjective life expectancy significantly
increases the likelihood of getting a mammogram. A 10%
age point increase in subjective life expectancy reduces
probability of mammography screening by about 0.6 per-
centage points. The results for the probit estimation are
quite similar to those of the OLS estimation for most
variables as can be seen in the right column of Table 2.
Noteworthy is, however, that the coefficient of physician
quality and life expectancy are a little bit higher using
probit specification compared to OLS. Moreover, we find
significantly smaller differences in the coefficients of the
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country dummies in the probit estimates, since the probit
model imposes the restriction that a predicted value has
to lie inside the range of 0 and 1.
Measurement error and endogeneity concerns
As stated in the introduction, we are seriously con-
cerned that subjective life expectancy as one of our
most important covariates suffers from measurement
error leading to attenuation bias. Measurement error
arises if an explanatory variable is measured with addi-
tive random errors. The higher the part of variability
that is due to errors, the larger is the magnitude of the
attenuation bias (e.g. [43]). Hurd, McFadden and Gan
[44] reveal that due to cognitive disability a lot of
respondents systematically provided focal-point answers
(0, 0.5 or 1) to the questions on subjective survival
probabilities in the sample of older individuals (aged 70
and over) in the Study of Assets and Health Dynamics
among the Oldest Old (AHEAD). A similar response
pattern comes up for women aged 50-69 years in the
SHARE-data with many focal answers at 0, 0.5 and 1 as
shown by Figure 1. These cannot represent the true
probabilities, both because the distribution of true prob-
abilities should be continuous and because the true
probabilities cannot be exactly either zero or one [44].
In the consequence the coefficient on that variable in an
Table 2 Estimation Results from OLS and Probit
(OLS) Mammogram (Probit) Mammogram
Physician Quality Index 0.107** (0.041) 0.116*** (0.042)
Life Expectancy 0.065** (0.030) 0.072** (0.031)
55 < = Age < 60 (d) 0.015 (0.015) 0.020 (0.018)
60 < = Age < 65 (d) 0.005 (0.013) 0.007 (0.015)
65 < = Age < 70 (d) -0.095** (0.032) -0.102*** (0.035)
Self Assessed Health -0.009** (0.004) -0.011** (0.005)
Number of ADL -0.029** (0.011) -0.032*** (0.012)
Heart Attack (d) -0.020 (0.021) -0.023 (0.024)
Stroke (d) -0.083** (0.031) -0.099*** (0.036)
Diabetes (d) -0.055** (0.019) -0.063*** (0.021)
Lung Disease (d) 0.012 (0.025) 0.010 (0.030)
ISCED Low (d) -0.056** (0.020) -0.066*** (0.021)
Verbal Fluency 0.002* (0.001) 0.003** (0.001)
Recall Delayed 0.001 (0.004) 0.000 (0.004)
Has Partner (d) 0.046*** (0.014) 0.053*** (0.016)
Children in Household -0.008 (0.013) -0.009 (0.014)
Doctor Visits = 10 (d) 0.041** (0.016) 0.046*** (0.018)
Regularly Drugs (d) 0.055*** (0.010) 0.064*** (0.011)
Hospital Stays = 2 (d) 0.019 (0.047) 0.016 (0.051)
Year and Country Dummies
Year 2006 0.006 (0.010) 0.007 (0.013)
Austria (d) 0.477*** (0.009) 0.318*** (0.004)
Germany (d) 0.251*** (0.006) 0.209*** (0.004)
Sweden (d) 0.634*** (0.008) 0.365*** (0.001)
Netherlands (d) 0.645*** (0.011) 0.378*** (0.002)
Spain (d) 0.470*** (0.021) 0.312*** (0.007)
Italy (d) 0.452*** (0.018) 0.314*** (0.008)
France (d) 0.614*** (0.010) 0.362*** (0.002)
Greece (d) 0.225*** (0.020) 0.191*** (0.014)
Switzerland (d) 0.271*** (0.010) 0.217*** (0.007)
Belgium (d) 0.538*** (0.009) 0.349*** (0.003)
Czech (d) 0.343*** (0.021) 0.257*** (0.012)
Poland (d) 0.238*** (0.025) 0.200*** (0.018)
Ireland (d) 0.285*** (0.023) 0.224*** (0.015)
Observations 6,893 6,893
Marginal effects; Standard errors in parentheses; (d) for discrete change of dummy variable from 0 to 1
* p < 0.10, ** p < 0.05, *** p < 0.01
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ordinary least squares regression will be biased towards
zero.
In addition, following the discussion of Fang et al. [23]
the impact of subjective life expectancy on investment in
health is endogenous, mainly due to reversed causality.
While investment in health might depend on subjective
life expectancy (which is to be analysed here), subjective
life expectancy is also likely to depend on investment in
health. Individuals who generally invest more in health
might believe in a pay-off of their behaviour, resulting
in the expectancy of a longer life. We follow Fang et al.
[23] and Bloom et al. [45] in using age at death of
respondents’ parents (or their current age if still alive),
as well as age2, age3 and binary indicators of whether
the father or mother died at an age that fell in the range
of under 65, 66 to 70, 71 to 75, 76 to 80, 81 to 85, or
86 and over.N The instruments can be seen as proxies
for health endowment like genetic factors that are trans-
fused from parents to children. Individuals with older
parents are likely to have a better health endowment
than those whose parents died early, possibly due to a
genetic disease.
The identifying assumption here is that genetic factors
affect subjective life expectancy but not the decision to
get a mammography screening once health and subjec-
tive life expectancy are controlled for. According to our
strategy in the “Basic-Analysis” section, we perform both
linear Instrumental Variable Two-Stage Least Squares
(IV-2SLS) estimation (following Fang et al. [23]), and a
non-linear two-stage procedure following Newey [50} to
correct standard errors in the presence of a dichoto-
mous dependent variable in the second stage. The 2SLS
method is usually chosen even in cases where the
dependent variable is dichotomous (e.g. Wooldridge
[46]) since strong specification assumptions are required
to justify the Newey [47] method. We present both for
completeness and find quite similar results with all
specifications.
Table 3 reports the results of linear and non-linear
two-stage procedure.O While the other coefficients
remain quite stable when the instrumental variables
regression is performed, the impact of subjective life
expectancy increases.P
The change is as predicted. It indicates that the effect
of life expectancy is strongly underestimated when mea-
surement error and endogeneity is not taken into
account. Subjective life expectation heavily increases the
probability of investing in one’s own health (by taking a
mammogram). Specifically, the estimates imply that a
10%age point increase in this subjective probability
reduces probability of mammography screening by about











0 .2 .4 .6 .8 1
Probability of living in ten years
Figure 1 Heterogeneity of survival beliefs and measurement error.
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before (0.6 percentage points) and still significant on the
10% level. Possibly, this effect is too high, since the large
standard errors associated with the IV approach leads to
large 90% confidence intervals of [0.0073438; 0.4492358].
However, this result does not seem to be due to weak
instruments as the F-statistics exceeds the Staiger-Stock
rule-of-thumb of 10 [48], when testing for the exclusion
of the instruments in the first-stage regression. Further-
more, over-identification tests support the validity of our
instruments. If one is willing to assume that the mother’s
age of death is exogenous to the individual mammogra-
phy screening decision, the hypothesis that all other
instruments are valid cannot be rejected.
Again, most of the coefficients in the IV-Probit Model
are quite similar to those of the IVOLS Model, as can
be seen in the right column of Table 3. However, the
impact of life expectancy is about 40 percent higher
(0.361 versus 0.256) in the IV-Probit Model compared
Table 3 Estimation results from IV OLS and IV Probit model
(IV-OLS) Mammogram (IV-Probit Model) Mammogram
Second Stage Regression
Physician Quality Index 0.108*** (0.039) 0.115*** (0.042)
Life Expectancy 0.256* (0.131) 0.361* (0.203)
55 < = Age < 60 (d) 0.012 (0.015) 0.015 (0.018)
60 < = Age < 65 (d) -0.001 (0.012) -0.003 (0.015)
65 < = Age < 70 (d) -0.091*** (0.031) -0.094*** (0.036)
Self Assessed Health 0.000 (0.009) 0.004 (0.012)
Number of ADL -0.025** (0.011) -0.025** (0.012)
Heart Attack (d) -0.012 (0.019) -0.009 (0.023)
Stroke (d) -0.083** (0.033) -0.098** (0.041)
Diabetes (d) -0.048*** (0.018) -0.051** (0.022)
Lung Disease (d) 0.022 (0.027) 0.025 (0.031)
ISCED Low (d) -0.054*** (0.020) -0.061*** (0.021)
Verbal Fluency 0.002* (0.001) 0.002 (0.001)
Recall Delayed 0.000 (0.004) -0.001 (0.004)
Has Partner (d) 0.046*** (0.014) 0.052*** (0.017)
Children in Household -0.007 (0.012) -0.008 (0.014)
Doctor visits = 10 (d) 0.040** (0.016) 0.045** (0.018)
Regularly Drugs (d) 0.057*** (0.010) 0.065*** (0.011)
Hospital Stays = 2 (d) 0.022 (0.048) 0.020 (0.055)
Year and Country Dummies
Year 2006 0.003 (0.009) 0.003 (0.013)
Austria (d) 0.493*** (0.016) 0.326*** (0.006)
Germany (d) 0.263*** (0.011) 0.220*** (0.007)
Sweden (d) 0.644*** (0.011) 0.368*** (0.003)
Netherlands (d) 0.649*** (0.010) 0.379*** (0.002)
Spain (d) 0.466*** (0.019) 0.309*** (0.008)
Italy (d) 0.453*** (0.017) 0.313*** (0.008)
France (d) 0.622*** (0.013) 0.365*** (0.003)
Greece (d) 0.236*** (0.024) 0.200*** (0.016)
Switzerland (d) 0.277*** (0.011) 0.221*** (0.007)
Belgium (d) 0.554*** (0.016) 0.356*** (0.006)
Czech (d) 0.387*** (0.036) 0.287*** (0.022)
Poland (d) 0.263*** (0.031) 0.223*** (0.022)
Ireland (d) 0.296*** (0.023) 0.231*** (0.014)
Observations 6,893 6,893
F-Stat. instruments first stage 14.54
Overid. Statistics2 27.15 (p = 0.101)
Marginal effects; Standard errors in parentheses
(d) for discrete change of dummy variable from 0 to 1
* p < 0.10, ** p < 0.05, *** p < 0.01; 2p-values in parenthesis
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to the IV-OLS Model. Moreover, once more the coeffi-
cients of the country dummies in the IV-Probit esti-
mates are significantly smaller compared to the IV-OLS
estimates. However in both models they remain always
jointly significant indicating huge differences across
countries that are not picked up by individual differ-
ences in our observed variables Q.
Discussion and conclusion
Breast cancer is the main cause of cancer-mortality
among women in Europe. Screening mammography
helps to detect breast cancer before it becomes invasive,
and mortality can be significantly reduced by regularly
mammography screening. Moreover, for women aged
50- 69 years mammography screening has proven to be
highly cost-effective. Even though mammography is offi-
cially recommended both on the national and European
level for this group of women, screening rates in most
European countries remain far from 100 percent and
reasons for underparticipation remain unclear. The pur-
pose of this paper was to conduct an empirical test of
certain hypotheses implied by economic theory concern-
ing the determinants of mammography screening focus-
ing on European women aged 50-69 years using the
SHARE data-base. The results indicate that better edu-
cation, being married, younger age and better health
consistently associated with higher rates of screening
take-up. These results suggest that additional efforts
may be needed to inform and convince the women liv-
ing alone but also the elderly and women in poor health
of the preventive benefits of mammography. Certain
interventions such as invitations appointments and tele-
phone calls have shown to be effective at increasing
uptake (compare [13]).
The impact of physician quality and subjective life
expectancy was of special interest in this paper. Having
a family physician who generally complies with indicated
geriatric assessments - as a proxy for physician quality -
has a strongly significant positive effect on mammogra-
phy screening propensity. Specifically, our estimates
indicate on average 10.7 percentage points higher
screening rates among respondents whose family physi-
cian performs all geriatric assessments relative to those
whose doctor does not undertake any evaluation. This
result is consistent with agency theory suggesting that
physicians act on behalf of their less informed patients.
This result may imply that interventions could address
the physicians as key communicator since the percen-
tage of physicians who recommend mammography
screening in Europe may be too low. In example, a
study from Switzerland reveals (compare [49]) that
among clinically practising physicians, only 22%
reported generally prescribing biannual screening mam-
mography’s for women aged 50-69. Thus, there might
be a need to educate physicians regarding the preventive
benefits of mammography screening.
Finally, we find that subjective life expectancy strongly
influences screening probability once the measurement
error is controlled for. Women who expect a longer life
are much more inclined to invest in mammography
screening than women who believe to live a few more
years only. In terms of health policy implications, this
result suggests that health promotions programs which
include discussions that increase subjective survival
expectations may provide suitable leverage to increase
screening rates.
End notes
A The incidence rates are generally slightly increasing
with age. For example in Denmark 319 per 100,000
women aged 50 to 69 years compared to 358 women
aged 70+ got the diagnosis of breast cancer in 2002. But
this pattern does not hold for each country [50].
B There is serious controversy regarding the effective-
ness and cost-effectiveness of mammography screening
especially for women younger than 50 years and older
than 70 years. Thus we focus on women aged 50-69
years.
C Maurer [41] as well as Schmitz and Wübker [42]
used physician quality to explain influenza vaccination
decision in Germany and Europe using the SHARE. We
base our paper on the quality score introduced by
Maurer [41].
D The phenomenon is named after the legendary
American baseball player Mickey Mantle who exhibited
a very unhealthy behaviour because he expected to die
at an early age because several of his family members
died of a rare hereditary disease at a young age.
E For more details on the sampling procedure, ques-
tionnaire contents and fieldwork methodology, readers
should refer to Börsch-Supan and Jürges [51].
F For example Yaskaskas et al. [52] show that women
with disabilities are less likely than those without dis-
abilities to receive a physician recommendation for
screening mammography.
G This variable describes the number of limitations
with activities of daily living (ADL). Six activities are
included: Dressing, including putting on shoes and
socks, Walking across a room, Bathing or showering,
Eating, such as cutting up your food, Getting in and out
of bed, using the toilet, including getting up or down.
H The International Standard Classification of Educa-
tion (ISCED) was designed by UNESCO in the early
1970’s to serve as a tool to facilitate comparisons of
education statistics and indicators of different countries
on the basis of uniform and internationally agreed defi-
nitions. The higher the ISCED value the higher the edu-
cation-level. The levels are as follows defined: Level 0:
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Pre-primary education; Level 1: Primary education or
first stage of basic education; Level 2: Lower secondary
or second stage of basic education; Level 3: (Upper) sec-
ondary education; Level 4: Post-secondary non-tertiary
education; Level 5: First stage of tertiary education (not
leading directly to an advanced research qualification);
Level 6: Second stage of tertiary education (leading to
an advanced research qualification, e.g. a Ph.D.). We
define low education by ISCED values between 0 and 2.
I The indicator used by Schmitz and Wübker [42] dif-
fers slightly from the one that Maurer [41] uses. The
reason is, firstly, that one question ("How often does
your GP check your weight?”) is only asked in the first
wave. Schmitz and Wübker [42] ignore this one and use
only five instead of six questions. Furthermore, Maurer
does not weight the answers but assigns a 1 if the GP
asked a specific question during at least some visits. The
pros and cons of this approach can be debated. On the
one hand, Maurer’s method comes with an information
loss. On the other hand, his approach might be more
robust to recall error as it is easier to remember if a GP
ever asked this question than how regular she does.
However, we tried both quality scores and did not find
qualitative differences in our results. In addition we
tested analogue to Schmitz and Wübker [42] different
weighting schemes of the questions in order to test
robustness of the results. We find only small differences
in our results. The results are available upon request.
J The data are available upon request from the
authors. Most guidelines recommend an endoscopic
examination (colonoscopy) of the colon from the age of
50 for both men and women [53] with a frequency that
varies in order to detect colon cancer in its earliest
stages. In the SHARE people are asked whether a physi-
cian recommended a colonoscopy in the last two years.
K It turns out that less than 1% (55 observations) of all
observations have a predicted value outside the range of
0 and 1. We feel that this is a reasonably low figure.
L This basic result holds independently of the refine-
ment of the physician quality measure.
M Alternatively, women who are treated by a physician
with a one standard deviation higher quality score have
roughly 3 percentage points’ higher screening rates.
N Good instruments should show a considerable
explanatory power for subjective life expectancy but
must not affect the decision to undergo a mammogra-
phy screening once the remaining explanatory variables
are controlled for.
O Additional file 1: Table A 1 reports the first-stage
results from two-stage estimation. The dependent vari-
able is self-stated probability of being alive in about 10
years. Clearly, health status as measured by self assessed
health is a very important determinant of life
expectancy. Moreover, parents’ ages at death have large
and significant effects in the expected direction. For
instance, having a father who died between 65 and 69
years reduces the subjective probability of being alive in
about 10 years by 4.5 percentage points, ceteris paribus
(compared to those women, whose father is still alive).
The F-test for the joint significance of the parental age
at death variables is 14.54 indicating that the instru-
ments are not weak.
P Note, however that the coefficients measuring health
status (e.g. Self Assessed Health) change in the IV-OLS
compared to OLS. This is due to the correlation of the
health measures with the instruments.
Q Unfortunately there are no tests for a) weak instru-
ment and b) over-identification of instruments in clus-
ter-robust IV-Probit models. However, the results of the
F-test and over identification test in the linear model
support the validity of our instruments and do not indi-
cate that the robustness of the results suffer from weak
instruments.
Additional material
Additional file 1: Table A1. First-Stage IV Regression Results: Predicting
Life Expectancy.
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